ICU Medical Inc
ICUI
Company Profile
Business description
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Contact
951 Calle Amanecer
San ClementeCA92673
USAT: +1 949 366-2183
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
15,000
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,094.10 | 12.40 | 0.14% |
CAC 40 | 7,854.61 | 67.63 | 0.87% |
DAX 40 | 23,674.53 | 315.35 | 1.35% |
Dow JONES (US) | 46,142.42 | 124.10 | 0.27% |
FTSE 100 | 9,228.11 | 19.74 | 0.21% |
HKSE | 26,535.35 | 9.50 | -0.04% |
NASDAQ | 22,470.72 | 209.40 | 0.94% |
Nikkei 225 | 45,183.78 | 119.65 | -0.26% |
NZX 50 Index | 13,231.66 | 111.63 | 0.85% |
S&P 500 | 6,631.96 | 31.61 | 0.48% |
S&P/ASX 200 | 8,806.60 | 14.40 | 0.16% |
SSE Composite Index | 3,837.01 | 5.35 | 0.14% |